CA
NZ
UK
AU
IND
US
Alleima's stock surged 7% after the company reported a second-quarter revenue beat, exceeding investor expectations. This development has sent ripples through the industrials sector, with analysts noting the positive implications for the industry. As the company's revenue growth outpaced forecasts, investors are cheering the …
Fastenal (NASDAQ: FAST) has named Jeffery Watts as its next chief executive, with the transition set to take effect in mid-July. The industrial distributor also elected Watts to its board, formalizing a leadership shift that includes a $650,000 base salary and performance-based incentives tied …
John Deere Receivables LLC has introduced an amendment that limits the share of defaulted notes to a maximum of 10% of the overall issuance. This parameter governs whether underwriters that remain solvent must assume the remaining obligations or whether the transaction can be unwound. …
HealthLynked has brought back a financial veteran to steer its Nasdaq uplisting and secure a capital raise of approximately Seven Million Five Hundred Dollars, a move that arrives as shares hover near the midpoint of their 52‑week range. The healthcare technology company, which connects …
Silence Therapeutics plc has entered into a separation agreement with its chief financial officer, Craig Tooman, concluding his tenure with a multi‑million‑dollar arrangement. The agreement, which becomes effective in mid‑December 2025, provides continued salary, a lump‑sum payment, and accelerated vesting of equity awards, underscoring …
BioRestorative Therapies has undergone a leadership transition following the resignations of two key executives, who assert they are owed severance payments. The disagreement stems from differing interpretations of whether recent changes in board composition triggered specific provisions in their employment agreements. The company has …
A surge in unplanned family health crises is reshaping the palliative care sector, forcing providers to adapt to a wave of late-stage enrollments from patients with no prior care arrangements. The shift comes as estranged relatives, often unprepared for sudden medical decisions, turn to …
Inhibrx Biosciences has secured a credit facility with a total commitment of $500 million and has drawn $100 million to support its clinical development programs. The agreement with Oxford Finance provides the company with the ability to draw an additional $225 million in $50 …
Price decline follows earnings release · Market reaction contrasts with financial results · Next catalyst: Full-year 2026 outlook update
Arcutis Biotherapeutics has expanded its board of directors with the addition of Christopher Peetz, a key executive from Mirum Pharmaceuticals. This appointment aligns with the company’s strategic focus on commercializing its ZORYVE franchise and advancing its pipeline in immuno-dermatology. As Arcutis continues to establish …
Please wait processing your request...